



PHASE TWO RESULTS FROM THE GEMINI QUALITY IMPROVEMENT PROJECT

This study was supported by an investigator grant from Bayer US LLC.

Authors: Katherine W. Kwon¹, Roy G. Marcus¹, Minesh Rajpal², Douglas Eckhardt¹, Jie Pu¹

¹ Panoramic Health, ² Southwest Kidney Institute

The GEMINI Project




Target: Patients with Type 2 Diabetes AND CKD stages 2-4 throughout the Panoramic Health network




Phase 1: Educational outreach to all Panoramic Health-affiliated providers about GDMT



Phase 2: Designated physician champions receive individual performance data and provide peer mentoring



Conclusions



Facilitating peer mentoring through physician champions did not lead to additional improvement in selected practices.




Within an individual practice, providers had different GDMT use at baseline and different rates of change over the course of the GEMINI project.



Use of nonsteroidal MRA showed improvements but uptake in eligible patients remained low. GLP1a medications, though not yet included in GDMT guidelines for diabetic nephropathy, had a much higher rate of use.

Total Patients	Pre	Post
	30,805	27,889
RAASI Use	70.8%	69.1%
SGLT2i Use	39.2%	44.0%
GLP1 Use	24.9%	28.2%
sMRA Use	8.7%	8.6%
nsMRA Use	4.7%	5.6%

Variability in GDMT Use and Improvement Within Practice A



¹ Owns equity in Panoramic Health.